Status unknownNCT00849537Updated Feb 24, 2009

The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy

A Phase 1/2 interventional study of Triamcinolone in Diabetic Retinopathy, sponsored by Shahid Beheshti University of Medical Sciences. Status unknown at 3 sites in Iran. Per ClinicalTrials.gov, last updated 2009-02-24.

Sponsored by Shahid Beheshti University of Medical Sciences · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2009), so the status shown — last known as Recruiting — may be out of date.

Phase: Phase 1/2
Study type: Interventional
Allocation: Randomized
Sex: All

Study summary

In this study, regressed proliferative diabetic retinopathy, very severe, severe and moderate non-prolifrative diabetic retinopathy patients who were going to have a cataract surgery, underwent a complete eye examination, OCT, FAG and color photography 2 weeks prior to their operation. All patients divided in two: 1) control group (Phyco,PCIOL), 2) triamcinolone treatment group (Phaco with PCIOL+IVT). One month after surgery a complete eye examination will be done especially; IOP and endophthalmitis. A 6 month follow-up will be done for these two groups and diabetic retinopathy progression will be checked.

Conditions studied

Diabetic Retinopathy

Browse trials for

Keywords

Triamcinolon
Cataract
Diabetic retinopathy
non-proliferative retinopathy

In context

Diabetic Retinopathy

791 studies on the registry are indexed under Diabetic Retinopathy; 139 are open to participants now.

Browse Diabetic Retinopathy studies →

Lead sponsor

Shahid Beheshti University of Medical Sciences is the lead sponsor of 229 studies on the registry; 19 are open to participants now.

Browse Shahid Beheshti University of Medical Sciences studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diabetic patients with non-proliferative diabetic retinopathy and regressed PDR

Exclusion criteria

Exclusion Criteria:

Uncontrolled HTN
History of glaucoma
Active PDR
NVI
TRD
Any ophthalmic operation
Renal problem(cr>3)
CVA
Uveitis

Study design

Phase: Phase 1 / Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Single (Participant)

Study arms

Experimental
Triamcinolone
Injection of intravitreal Triamcinolone
Drug: Triamcinolone

Interventions

DrugTriamcinolone
Injection of intravitreal Triamcinolone

What researchers measure

Primary outcomes

Macula diameter
Time frame: 6th week, 3, 6 months

Secondary outcomes

Diabetic retinopathy
Time frame: 6th weeks, 3 and 6 months later

Study locations

1 of 3 sites recruiting

Ophthalmic Research Centre
Tehran, Tehran Province 1666663111, Iran
Active, not recruiting
Siamak Moradian,MD
Tehran, Tehran Province 166666, Iran
Active, not recruiting
Tehran, Iran
Recruiting

Timeline

Tracking since Sep 25, 2026

Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered: Feb 23, 2009
First posted: Feb 24, 2009
Start: Apr 2008
Primary completionEst.: Apr 2009
CompletionEst.: Apr 2009
Last update: Feb 24, 2009

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Feb 24, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00849537
Lead sponsor: Shahid Beheshti University of Medical Sciences
First posted: Feb 24, 2009
Start date: Apr 2008
Primary completion: Apr 2009 (estimated)
Completion: Apr 2009 (estimated)
Last update: Feb 24, 2009

Study contacts

Siamak Moradian, MD

Contact

Moradian33195@yahoo.com

00982122592200

Dr. Siamak Moradian, MD

principal investigator · Shaheed Beheshti University Of Medical Science

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone

Other studies in this condition

Diabetic Retinopathy →

Other studies from this sponsor

Shahid Beheshti University of Medical Sciences →

Start the discussion